References
- O’Brien SG, Guilhot F, Larson RA, . Imatinib compared with interferon and low-dose cytarabine for newly diagnosed chronic-phase chronic myeloid leukemia. N Engl J Med 2003;348:994–1004.
- Druker BJ, Guilhot F, O’Brien SG, . Five-year follow-up of patients receiving imatinib for chronic myeloid leukemia. N Engl J Med 2006;355:2408–2417.
- Deininger M, O’Brien SG, Guilhot F, . International Randomized Study of Interferon versus STI571 (IRIS) 8-year follow-up: sustained survival, low rate for progression or events in patients with newly diagnosed chronic myeloid leukemia in chronic-phase (CML-CP) treated with imatinib (IM). Blood 2009;114(Suppl. 1): Abstract 1126.
- Baccarani M, Cortes J, Pane F, . Chronic myeloid leukemia: an update of concepts and management recommendations of European LeukemiaNet. J Clin Oncol 2009;27:6041–6051.
- Wei G, Rafiyath S, Liu D. First-line treatment for chronic myeloid leukemia: dasatinib, nilotinib, or imatinib. J Hematol Oncol 2010;3:47.
- Funke VAM, Medeiro CR, Lima DH, . Therapy of chronic myeloid leukemia with imatinibmesylate in Brazil: a study of 98 cases. Rev Bras Hematol Hemoter 2005;27:159–165.
- Silveira CAP, Daldegan MB, Ferrari I. Response to treatment with imatinib mesylate in previously treated chronic-phase chronic myeloid leukemia patients in Hospital de Base of Distrito Federal. Genet Mol Res 2011;10:2038–2048.
- Baccarani M, Saglio G, Goldman J, . Evolving concepts in the management of chronic myeloid leukemia: recommendations from an expert panel on behalf of the European Leukemia Net. Blood 2006;108:1809–1820.
- Campos MGV, Arantes AM, Oliveira JSR, . Chronic myeloid leukemia: a disease of youth in Brazil. Leuk Res 2010;34:542–544.
- Kantarjian HM, Talpaz M, O’Brien S, . Survival benefit with imatinibmesylate versus interferon-[alfa]-based regimens in newly diagnosed chronic-phase chronic myelogenous leukemia. Blood 2006;108:1835–1840.
- Palandri F, Castagnetti F, Lacobucci I, . The response to imatinib and interferon-α is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase. Haematologica 2010;95:1415–1419.
- Wang AH, Wang YY, Yao Y, . Summary of 615 patients of chronic myeloid leukemia in Shanghai from 2001 to 2006. J Exp Clin Cancer Res 2010;29:20.
- De Lavallade H, Apperley JF, Khorashad J, . Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis. J Clin Oncol 2008;26:3358–3363.